Countries citing papers authored by Ryotaro Kuroda
Since
Specialization
Citations
This map shows the geographic impact of Ryotaro Kuroda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryotaro Kuroda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryotaro Kuroda more than expected).
This network shows the impact of papers produced by Ryotaro Kuroda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryotaro Kuroda. The network helps show where Ryotaro Kuroda may publish in the future.
Co-authorship network of co-authors of Ryotaro Kuroda
This figure shows the co-authorship network connecting the top 25 collaborators of Ryotaro Kuroda.
A scholar is included among the top collaborators of Ryotaro Kuroda based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Ryotaro Kuroda. Ryotaro Kuroda is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
17 of 17 papers shown
1.
Kawabata, Atsufumi & Ryotaro Kuroda. (2002). [PAR (protease-activated receptor) as a novel target for development of gastric mucosal cytoprotective drugs].. PubMed. 120(1). 85P–87P.1 indexed citations
Honjo, Tomoko, et al.. (1993). [Antiemetic efficacy of granisetron in the treatment of pediatric cancer--(1). Clinical evaluation of granisetron at a dose of 40 micrograms/kg].. PubMed. 20(14). 2201–5.4 indexed citations
9.
Honjo, Tomoko, et al.. (1993). [Antiemetic efficacy of granisetron in pediatric cancer treatment--(2). Comparison of granisetron and granisetron plus methylprednisolone as antiemetic prophylaxis].. PubMed. 20(15). 2369–73.11 indexed citations
10.
Izumoto, Shuichi, Norio Arita, Y Ushio, et al.. (1988). [Growth activity of meningeal carcinomatosis--immunohistochemical study using anti-BrdU monoclonal antibody].. PubMed. 40(2). 127–31.2 indexed citations
11.
Watanabe, Misa, et al.. (1977). [Clinical study on penetration of antibiotics into cerebrospinal fluid (second report),-Study on intravenous administration of sodium cephalothin with mannitol solution (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 5(2). 137–43.1 indexed citations
12.
Hayakawa, Tõru, et al.. (1975). Argon laser treatment of brain tumor sensitized with acridine orange.. PubMed. 26(12). 61–7.6 indexed citations
13.
Hayakawa, Tõru, et al.. (1970). Intrathecal Chemotherapy. British Journal of Cancer. 24(3). 489–497.11 indexed citations
14.
Yamada, Ryoji, et al.. (1968). Experimental studies of the chemotherapy of brain tumors. 1. Distribution of cytostatic agents in the serum, cerebrospinal fluid and brain tissue after intravenous, intracarotid and intrathecal administration.. PubMed. 18(4). 373–88.3 indexed citations
15.
Hayakawa, T, et al.. (1968). Experimental studies on the chemotherapy of brain tumors. 2. Localization of cytostatic agents in central nervous tissue after intravenous, intracarotid and intrathecal administration.. PubMed. 18(4). 389–95.3 indexed citations
16.
Jinnai, Dennosuke, et al.. (1967). [Chemotherapy of brain tumors, with reference to the selection of carcinostatics for intrathecal administration and the distribution of concentration of carcinostatics in various administrations].. PubMed. 19(4). 333–7.2 indexed citations
17.
Mogami, H, et al.. (1967). Selection of cytostatic agents for intrathecal chemotherapy of brain tumor.. PubMed. 17(3). 333–40.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.